Pfizer Vows Disciplined Financial Allocation; Will Not Chase Price For Buyouts In Markets Like India
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - As the socioeconomic shift gains pace and healthcare is given a higher priority by governments, emerging markets like China, Brazil and India have received heightened attention from global companies looking for deal-making opportunities, but lately, unexpected hurdles have cropped up in the way. "Overly exuberant expectations" may be making future alignments hard, say high level seasoned M&A experts